Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| and the team have done an amazing great job building a sales and distribution network that can help us scale TOMI to be a much larger company |
| Adhering to the industry trends previously discussed, our innovative product, the SteraMist Integration System, or SIS, is gaining notable traction |
| They did a terrific job and making sure that all investors, including these new ones, are successful in years ahead going forward |
| These accomplishments underscore the diverse applications and positive outcomes associated with our innovative solutions |
| The recent collaboration with Vizient GPO holds promise for expansion in the healthcare sector |
| This collaboration marks a significant milestone in our efforts to broaden our reach and strengthen our position in the health care market |
| The past 2 months have been marked by significant activity, and I am optimistic that the efforts invested will yield positive awareness by the end of this year, with an even greater impact anticipated in the coming years |
| They maintain a positive outlook on the collaboration with the German biotechnology company referenced during our last call, anticipating the conversion of this partnership into several orders for our CES or custom environment system |
| Furthermore, our expanded range of SteraMist products and applications, combined with recent partnerships, is poised to reinforce this alignment |
| That said, our revenue was up 5% for the 9-month period, and we are optimistic about our high-margin business model and its ability to drive future sustained profitability as we scale the business |
| I appreciate your patience, and I’m encouraged that our strategic initiatives position the company to drive sustained revenue growth in the near-term |
| We are encouraged by long-term disinfection and decontamination trends in aseptic manufacturing in the biopharmaceutical sector and general worldwide pandemic preparedness |
| Looking ahead to 2024, we anticipate a significant acceleration in the momentum of our sales network |
| We continue to see positive signs with our SteraMist iHP service team as we saw quarter-over-quarter revenue growth of 59% and year-over-year growth of 16% through September |
| Our current pipeline and backlog remains healthy |
| The variety of well-established partners ranging from the collaboration with design and engineering groups of pharmaceutical facilities to the decades of expertise and enclosure decontamination representation, combined with our new product lineup, positions SteraMist iHP for significant growth, especially in the life sciences |
| This presents another promising prospect for a collaboration in the realm of long-term integration |
| We believe the competitive advantages to TOMI’s iHP SteraMist technology is well aligned with these prevailing trends within the biopharmaceutical sector |
| We anticipate the agreement will better position us in providing education to the food safety markets through the education of the advantages of the SteraMist platform of products and expand our sales channels as well as our customer bases on the food safety markets |
| A big thank you to our team around the world who has laid the foundation for our company to become the world’s leader in the disinfection decontamination space |
| And if we execute, we should be able to drive sustained profitability going forward |
| Additionally, the recent additions to our customer base in the food safety sector, acting as referrals for our technology, marked first-time progress for us |
| These developments aim to enhance awareness among facilities, ensuring iHP technology caters effectively to evolving industry needs |
| We are also working with the Canadian distributor group, Tecnimont that we released earlier in the year, and they are gaining a lot of traction on the transport with designers of ambulances, in which we are going to work with them on certain mounting devices because that is their specialty |
| It is my belief that we are poised to move through to profitability in the fourth quarter |
| As I hope you have garnered from our remarks, a key strategic shift in our business this year has been the establishment of a robust partner and reseller network to more efficiently expose our product to the right customers |
| is a trusted supplier of high-quality clinical and laboratory equipment |
| Our strategic collaboration with recent partners and representatives specializing in the industry positions SteraMist iHP to market and sell this product line effectively |
| The expansion of our sales infrastructure in 2023 has been substantial, and we will maintain a strong sense of optimism as we approach the conclusion of 2023 |
| Notably, we successfully sold our SteraPak to Simplot, a leading international food and agricultural company headquartered in Boise, Idaho |
| Statement |
|---|
| While quarter three presented timing challenges on the revenue front, we made significant achievements in acquiring new customers, particularly within the industry closely monitored by our shareholders, that is, food safety |
| Revenue declined during the quarter due to the timing of customer orders and the related revenue recognition |
| The decline in our gross profit was due to our product mix and sales |
| As we announced in August, Pfizer Rocky Mount engaged our iHP service to conduct emergency decontamination within their facility, which suffered substantial damage to the tornado |
| As we all know, or we all should know, it’s a significant problem throughout the United States, and it’s affecting educational systems, affecting police |
| Adjusted EBITDA was a loss of $807,000 compared to a loss of $571,000 |
| A few years ago, I tried to establish Vice Presidents of Sales to head up each vertical, and this was just a mistake and cost us valuable time |
| The consolidated operating loss was $901,000 compared to $654,000 |
| We still have to endure some crash testing that’s required in the region |
| Our consolidated net loss was $901,000 or $0.05 per basic and diluted share compared to $653,000 or $0.03 per basic share |
| Our ongoing partnership with Solaris, as highlighted in the press release from the previous quarter, continues to be of significant importance |
| It’s obviously a lot more difficult to bring in many one or two just from standpoint, education and paper |
Please consider a small donation if you think this website provides you with relevant information